Investor Watch Series | Funding – Who to Watch | S2 E1 Purdue Seeks Biotech Partnerships

Jul 3, 2020 | Digital Media, Investor Watch Series, Video

Investor Watch

Welcome To Investor Watch

In this series will be going over trials, research and other clinical verticals that receive funding. Below are the ones we cover in this episode:

  • #Purdue Spin-off Secures $400K for Novel Approach to Treating Lung & Thyroid Cancers & Seeks Biotech Partnerships: Lung and thyroid cancers frequently have deadly consequences and most families can connect with the loss of a loved one due to these killers. Hence, its promising that yet another Purdue spin-off is bringing a novel approach to treating these conditions and the lead investigational product is moving closer to clinical trials. Funding always helps, and recently KinaRX received a $399,933 SBIR Phase I grant from the National Cancer Institute. The funding will help to advance the startups novel platform aimed at producing more effective drugs to treat lung and thyroid cancers. This advanced, Purdue-discovered platform targets gene mutations that help cancers grow and expand within the body. KinaRX is in the market as well to find partnerships.…
  • #AbbVie Inks Deal with Alpine Immune Sciences for CD28/ICOS Inhibitor: Pays $60m Upfront & Up to $805m in Downstream Payments: A Seattle-based biotech developing innovative treatments for cancer and autoimmune/inflammatory diseases secured a $60 million cash payment and up to $805 million in potential drug development, regulatory and commercial milestone payments from major pharmaceutical company AbbVie. Publicly traded via a reverse merger, Alpine Immune Sciences (NASDAQ: ALPN) positions itself as a leading clinical-stage immunotherapy company that was able to negotiate an important drug development and commercialization collaboration deal involving an exclusive worldwide option and license agreement for their proprietary lead compound, ALPN-101. Based on the financial track record thus far, the deal looked like the smart thing to do.…
  • #Engrail #Therapeutics Launches With $32 Million in Series A Financing: Engrail Therapeutics announced the close of a $32 million Series A financing round. Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led the round. The Company plans to use the proceeds from the financing to support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator. Engrail’s scientific approach begins with a thorough biological understanding of disease and rational therapeutic targeting. This in turn enables the company to identify compounds with greater opportunity to address unmet patient needs. When combined with a comprehensive view of clinical development strategy, regulatory considerations, intellectual property and optimal commercial positioning, this approach will allow Engrail to acquire high-quality assets with a lower-risk path to market. Engrail expects to acquire assets with validated mechanisms through various licensing and co-development programs to ultimately catalyze a diverse portfolio of therapies to treat diseases of the nervous system.…


Pin It on Pinterest